他汀类药物使用与全身性骨关节炎患者MRI软骨下骨髓病变加重的关联:来自骨关节炎倡议数据的纵向分析
基于骨关节炎倡议数据,在基线临床检查有Heberden结节(全身性骨关节炎表型)的参与者中,经倾向性评分匹配后分析他汀使用与24个月膝关节MRI软骨下骨髓病变(BML)加重的关联。在基线BML无/轻微组,他汀使用与BML评分加重(OR 0.62,95%CI 0.39-0.98)及受累亚区数量增加(OR 0.54,95%CI 0.33-0.88)的 odds 降低相关;在Heberden结节阴性者或基线BML中/重度组未见此关联。作者认为,在有心血管他汀适应证且为全身性骨关节炎表型(Heberden结节阳性)的患者中,他汀使用可能仅对基线BML无/轻微亚组具有保护作用。
要点
- 在Heberden结节阳性且基线BML无/轻微者中,他汀使用与BML评分加重 odds 降低相关(OR 0.62,95%CI 0.39-0.98)。
- 同一亚组中,他汀使用与受累亚区数量增加的 odds 降低相关(OR 0.54,95%CI 0.33-0.88)。
- Heberden结节阴性者或基线BML中/重度者中未观察到他汀使用与BML加重的关联。
核心结论
- 在有心血管他汀适应证且为全身性骨关节炎表型(Heberden结节阳性)的患者中,他汀使用可能仅对基线BML无/轻微的亚组具有对抗骨关节炎相关软骨下骨损伤的保护作用。
研究设计与样本
- 基于骨关节炎倡议(OAI)数据的纵向分析,纳入基线临床检查有Heberden结节(HN+)的参与者,使用基线及24个月半定量MRI骨关节炎膝关节评分评估BML体积和受累亚区数量变化。
关键影像表现/征象
- 基线BML无/轻微定义为14个膝关节亚区中受累≤2个且最大BML评分≤1。
- 基线BML中/重度定义为不满足无/轻微标准者。
- Heberden结节阳性且基线BML无/轻微者经倾向性评分匹配后共332膝(他汀使用者166膝,非使用者166膝)。
- Heberden结节阳性且基线BML中/重度者经倾向性评分匹配后共380膝(他汀使用者190膝,非使用者190膝)。
诊断标准与关键数值
- 在Heberden结节阳性且基线BML无/轻微者中,他汀使用与BML评分加重的OR为0.62(95%CI 0.39-0.98)。
- 在Heberden结节阳性且基线BML无/轻微者中,他汀使用与受累亚区数量增加的OR为0.54(95%CI 0.33-0.88)。
- 在Heberden结节阴性者或Heberden结节阳性且基线BML中/重度者中,未观察到他汀使用与BML评分加重或受累亚区数量增加的关联。
临床应用与阅片要点
- 对全身性骨关节炎表型(Heberden结节阳性)且基线BML无/轻微的患者,他汀使用可能与BML评分加重及受累亚区数量增加的 odds 降低相关。
- 对Heberden结节阴性或基线BML中/重度的患者,他汀使用与BML加重的关联未观察到。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To determine the association between statin therapy and knee MRI-detected subchondral bone marrow lesion (BML) longitudinal worsening in patients with Heberden's nodes (HNs) as the hallmark of generalized osteoarthritis (OA) phenotype.
METHODS: All participants gave informed consent, and IRB approved HIPAA-compliant protocol. We assessed the worsening in BML volume and number of affected subregions in the Osteoarthritis Initiative (OAI) participants with HNs at baseline clinical examination (HN+), using the semi-quantitative MRI Osteoarthritis Knee Scores at baseline and 24 months. Participants were classified according to baseline BML involvement as "no/minimal" (≤ 2/14 knee subregions affected and maximum BML score ≤ 1) or "moderate/severe." Statin users and non-users were selected using 1:1 propensity-score (PS) matching for OA and cardiovascular disease (CVD)-related potential confounding variables. We assessed the association between statin use and increasing BML score and affected subregions using adjusted mixed-effect regression models.
RESULTS: The PS-matched HN+ participants (63% female, aged 63.5 ± 8.5-year-old) with no/minimal and moderate/severe BML cohorts consisted of 332 (166:166, statin users: non-users) and 380 (190:190) knees, respectively. In the HN+ participants with no/minimal BML, statin use was associated with lower odds of both BML score worsening (odds ratio, 95% confidence interval: 0.62, 0.39-0.98) and increased number of affected subregions (0.54, 0.33-0.88). There was no such association in HN- participants or those HN+ participants with baseline moderate/severe BML.
CONCLUSION: In patients with CVD indications for statin therapy and generalized OA phenotype (HN+), statin use may be protective against the OA-related subchondral bone damage only in the subgroup of participants with no/minimal baseline BML.
KEY POINTS: • Statin use may reduce the risk of subchondral bone damage in specific osteoarthritis patients with a generalized phenotype, minimal subchondral bone damage, and cardiovascular statin indications.
引用
- Mohajer, Guermazi, Conaghan, et al. Statin use and MRI subchondral bone marrow lesion worsening in generalized osteoarthritis: longitudinal analysis from Osteoarthritis Initiative data. Eur Radiol. 2022. PMID: 35043291. doi:10.1007/s00330-021-08471-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。